All eyes on Biogen's experimental Alzheimer's drug as FDA deadline nears
Less than a week out from the deadline for the U.S. Food and Drug Administration's decision on Biogen Inc.'s much-anticipated Alzheimer's drug, the biotech world is holding its breath for what has been described as a make-or-break product for the Cambridge company.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Rowan Walrath Source Type: news
More News: Alzheimer's | American Health | Biotechnology | Eyes | Food and Drug Administration (FDA) | Health Management